Effect of Crestor on Lipoprotein Metabolism in Humans

Completed · Phase 4

Conditions studied: Hypercholesterolemia

In brief

The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate the rate of removal of LDL from the blood. At the higher dose, the increased potency of Crestor is explained by a reduction in the production of LDL by the liver.

Key facts

Study ID

NCT00214617

Run by

Foundation for Atlanta Veterans Education and Research, Inc.

People needed

8

Starts

2005-01-01

Expected to finish

2006-02-01

Last updated by the study team

2017-06-20

Who can join

Age: 50 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• TG between 200 and 400 mg/dL
• LDLc between 160 and 250 mg/dL
• HDLc between 30 and 50 mg/dL for men and 40-65 mg/dL for women
• Lp(a) less than 30 mg/dL
• Age between 50 and 75 years

You may not qualify if…

• current lipid-lowering therapy,
• primary hypertriglyceridemia (TG>400 mg/dL),
• High HDL (HDL>70),
• high Lp(a), greater than 30 mg/dL
• presence of beta-VLDL on agarose electrophoresis,
• current use of immunosuppressive agents,
• hormone replacement therapy for women
• history of cancer, active liver disease or hepatic dysfunction (AST or ALT 1.5 x ULN (Upper Limit of Normal),
• excessive consumption of alcohol, and recent history of drug abuse.

Where it is running

• Atlanta Research and Education Foundation — Decatur, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.